The White House has withdrawn Heidi Overton’s nomination to lead the Food and Drug Administration after opposition from Senate Republicans complicated her path to confirmation, abruptly ending her candidacy just one day before a key committee vote.
The decision, announced Tuesday, leaves the Trump administration searching for another candidate to lead the federal agency responsible for overseeing the safety and effectiveness of prescription drugs, vaccines, medical devices and much of the nation’s food supply.
Overton’s nomination had encountered resistance over several politically sensitive issues, including vaccine policy, access to abortion medication and the regulation of flavored electronic cigarettes.
The political news that affects your wallet, your rights and your vote, broken down in plain language. Free in your inbox.
The withdrawal also exposed disagreements over whether Overton actually lacked enough Republican support to advance through the Senate.
Sen. Bill Cassidy, a Louisiana Republican who chairs the Senate Health, Education, Labor and Pensions Committee, challenged the administration’s explanation that insufficient congressional backing had prompted the decision.
Cassidy’s position raised questions about why the White House abandoned the nomination before lawmakers had an opportunity to vote.
The committee had been scheduled to consider Overton’s nomination Wednesday. Instead, the administration withdrew her name before the panel could formally decide whether to advance her nomination to the full Senate.
The FDA commissioner is one of the most influential federal health officials, overseeing decisions that affect prescription drug approvals, vaccine authorizations, food safety enforcement and the availability of medical treatments.
The position requires Senate confirmation, meaning a nominee must secure sufficient support from lawmakers before taking office.
Although Republicans control the Senate, the administration cannot necessarily count on unanimous support from its own party, particularly when nominees face disagreements over public health policy.
Overton’s withdrawal illustrates those tensions as Republicans debate the federal government’s role in regulating medical products and making decisions about vaccines and reproductive health care.
The administration has not publicly established when it will announce a replacement nominee.
Whoever Trump selects next will face Senate scrutiny over the same issues that complicated Overton’s nomination, including the FDA’s scientific independence, its approach to vaccine oversight and its regulation of abortion medication.
Until a permanent commissioner is confirmed, the agency can continue operating under its existing leadership structure, with senior officials carrying out its regulatory responsibilities.
The next nomination will determine who is positioned to lead an agency whose decisions directly affect millions of Americans who depend on prescription medications, vaccines, medical devices and federal food safety protections.





